1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Physician Views: When and where do oncologists see palbociclib fitting into the ER+, HER2- breast cancer landscape?

Physician Views: When and where do oncologists see palbociclib fitting into the ER+, HER2- breast cancer landscape?

  • August 2014
  • ID: 2387282
  • Format: PDF
  • Firstword Pharma


Analysts believe palbociclib is likely headed for an accelerated approval to treat a subset of breast cancer, which would give Pfizer a big leg up over competitors like Eli Lilly and Novartis with less advanced compounds in the CDK 4/6 inhibitor class.

Expectations for palbociclib were flying high in 2012 when Pfizer reported preliminary results from the Phase II PALOMA-1 trial showing the drug improved progression-free survival (PFS) by 18.6 months when added to Femara in postmenopausal women with oestrogen receptor (ER) positive, HER2-negative locally advanced or metastatic breast cancer (26.1 months versus 7.5 months). In fact, the FDA found the early data compelling enough to grant the product breakthrough therapy status last year.

However, the waters were muddied this spring by updated PALOMA-1 results that were seen as a disappointment by many on the Street. Specifically, palbociclib's PFS advantage had narrowed considerably to only 10 months, while an interim look at the secondary endpoint of overall survival (OS) showed the compound failed to achieve significance (37.5 months for the combination versus 33.3 months for Femara alone).

The lack of improvement on the OS endpoint appeared to catch many by surprise given palbociclib's particular robust impact on PFS. Nonetheless, after discussions with the FDA, Pfizer announced its intentions to submit a filing for palbociclib this quarter, though the company declined to share whether the decision was being driven by itself or the agency. Either way, Pfizer followed through on the plan andcompleted submission of the application earlier this month.

Jefferies analyst Jeffrey Holford suggested the strong PFS data and "consistent improvement across other efficacy measures," along with a relatively clean safety profile strengthen Pfizer's case for approval of palbociclib.

Approval based on PALOMA-1 alone would be an important achievement for Pfizer. Analysts predict marketing applications for its closest competitors, such as Eli Lilly's bemaciclib and Novartis' LEE011, will not be ready before at least 2016, meaning the sooner palbociclib is approved the stronger foothold it will have.

Thus, to better understand the likelihood of an accelerated approval of palbociclib, as well as how it might fit into the commercial setting, FirstWord is this week polling US-based oncologists. Specifically we are asking them...

Given the small size (165 patients) and open-label design of the Phase II PALOMA-1 study, combined with the non-significant difference on overall survival at the interim update this spring, are the data showing palbociclib improved progression-free survival by 10 months in ER+, HER2- breast cancer patients sufficient to support an accelerated approval in this setting?
Based on previous experiences in this setting, such as iniparib (Phase II data failed to translate to OS benefit in Phase III) and Avastin (accelerated approval based on PFS later revoked when it did not improve OS), would the FDA be right to wait for data confirming a survival advantage before approving palbociclib in this setting?
Based on the data available for various CDK 4/6 inhibitors (eg, Eli Lilly's bemaciclib and Novartis' LEE011), how does Pfizer's palbociclib appear to stack up and what impact will this have on how much use it receives?
Does use of Femara (letrozole) in the adjuvant setting make the results of PALOMA-1 difficult to interpret?
What percentage of front-line patients with ER+, HER2- breast cancer do you expect to use palbociclib in 12 months from now?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on